CTNNA1 Antibody, HRP conjugatedСпецификацияОбъем | 50 мкг | Синонимы | Catenin alpha-1 (Alpha E-catenin) (Cadherin-associated protein) (Renal carcinoma antigen NY-REN-13), CTNNA1 | Клональность | Polyclonal Antibody | Организм | Human | uniprot | P35221 | Иммуноген | Recombinant Human Catenin alpha-1 protein (1-278AA) | Источник | Rabbit | Видовая специфичность | Human | Применение | ELISA | Примечание | Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. May play a crucial role in cell differentiation. | Клональность1 | Polyclonal | Изотип | IgG | Коньюгат | HRP | Буффер | Preservative: 0.03% Proclin 300<br />Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 | Форма | Liquid | Хранение | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. | Метод очистки | >95%, Protein G purified | Области исследований | Cancer, Signal transduction, Stem cells | Ссылка на страницу на сайте производителя | ссылка | | |
Информация для заказаОбласть использования: | Производство: | Cusabio | Метод: | Антитела | Объем: | 50 мкг | Кат. номер: | CSB-PA006164EB01HU | Цена (с НДС 20%): | по запросу | В корзину | Наименование: CTNNA1 Antibody, HRP conjugated. Примечание: дополнительная информация (на английском языке). |
|